Список проголосовавших за комментарий " <ul><li><strong>CBAY</strong> +41.6% (Kowa Pharmaceuticals America announces agreement with CymaBay Therapeutics to license gout compound)</li><li><strong>BLPH</strong> +24.1% (receives confirmation of the FDA's acceptance of all modifications proposed by the co to its Phase 3 program for INOpulse )</li><li><strong>OCUL</strong> +9% (announces additional successful results for Phase 3 clinical trial of Dextenza)</li><li><strong>ECA</strong> +5% (anticipates production growth from its core four assets from 4Q16 to 4Q17 will be in the upper range of, or exceed, its previously indicated growth plan of 15-20% Y/Y)</li><li><strong>SHAK</strong> +4.6% (to Join S&P SmallCap 600)</li><li><strong>NVLS</strong> +4.3% (initiated a process to explore and review a range of strategic alternatives)</li><li><strong>KOPN</strong> +3.5% (continued strength)</li><li><strong>DEPO</strong> +3.2% (continued strength)</li><li><strong>XRX</strong> +3% (continued strength)</li><li><strong>RYAAY</strong> +2.2% (reports Dec traffic rose 20% YoY)</li><li><strong>FOLD</strong> +1.4% (announced that the National Institute for Health and Care Excellence Highly Specialised Technologies Evaluation Committee has issued a positive final evaluation determination for reimbursed patient access to Galafold)</li><li><strong>CC</strong> +1.2% (to join S&P MidCap 400),</li></ul>"